Results for covariates translation from English to Maltese

hiv-1 rna <50 copies/ml by baseline covariates
hiv-1 rna <50 kopja/ml skont kovarjanti tal-linja bażi

baseline albumin and lean body weight were the most significant covariates influencing cl.
albumin u l-piż dgħif tal-ġisem fil-linja bażi kienu l-ko- varjabbli l-aktar sinifikanti li nfluwenzaw cl.

the individual effect sizes of these covariates were considered not clinically relevant.
id-daqsijiet tal-effett individwali ta’ dawn il-kovarjanti kienu kkunsidrati li mhumiex klinikament rilevanti.

no starting dose adjustment was considered necessary for any of the following covariates tested.
l-ebda aġġustament fid-doża tal-bidu ma kien ikkunsidrat li hu meħtieġ fi kwalunkwe mill-kovarjanti li ġejjin li kienu ttestjati.

covariates as baseline pasi, baseline lymphocyte count and age had modest effects on clearance;
varjanti bħal linea ta ’ basi pasi, linea ta ’ basi ta ’ l- ammont ta ’ limfoċiti w eta ’ kellhom effett moderata fuq l- eliminazzjoni; is- sess u l- oriġini etniku ma kellhomx effett.

a population pharmacokinetic analysis was performed to explore the potential effects of selected covariates on panitumumab pharmacokinetics.
twettqet analiżi farmakokinetika tal-popolazzjoni biex tesplora l-effetti potenzjali ta’ kovarjanti magħżula fuq il-farmakokinetika ta’ panitumumab.

the clearance model developed showed that body weight, gender, age, and serum creatinine were the main covariates.
il-mudell tat- tneħħija li żviluppa wera li l-piż tal-ġisem, is-sess, l-età, u l-krejatinina fis-serum kienu l-ko-varjanti prinċipali.

effects of these covariates on ribavirin clearance appear to be of limited clinical significance due to the substantial residual variability not accounted for by the model.
effetti ta’ dawn il-kovarjetajiet fuq it- tneħħija ta’ ribavirin jidhru li huma ta’ importanza klinika minħabba l-varjabilità sostanzjali residwa li ma tteħditx in konsiderazzjoni mill-mudell.

population pharmacokinetic analysis revealed that bsa and gender were the most significant covariates to explain inter-individual variability in pharmacokinetic parameters.
l-analiżi farmakokinetika tal-popolazzjoni wriet li l-bsa u s-sess tal-persuna kienu l-aktar kovarjabbli sinifikanti biex tiġi spjegata l-varjabilità fil-parametri farmakokinetiċi bejn l-individwi.

covariates as baseline pasi, baseline lymphocyte count and age had modest effects on clearance; gender and ethnic origin had no effect.
varjanti bħal linea ta’ basi pasi, linea ta’ basi ta’ l-ammont ta’ limfoċiti w eta’ kellhom effett moderata fuq l-eliminazzjoni; is-sess u l-oriġini etniku ma kellhomx effett.

a p-values compared efalizumab with placebo using logistic regression including baseline pasi score, prior treatment for psoriasis and geographical region as covariates.
a p-values ikkomparaw efalizumab ma’ plaċebo bl-użu ta’ logistic regression, inkluz linea ta’ basi pasi score, kura li ntuża qabel għal psorjażi, u reġjun ġeografiku bħal covariates.

however, the magnitude of effect of these covariates on trastuzumab emtansine exposure, suggests that these covariates are unlikely to have any clinically meaningful effect on trastuzumab emtansine exposure.
madankollu, id-daqs tal-effett ta’ dawn il-kovarjanti fuq l-esponiment għal trastuzumab emtansine, jissuġġerixxi li dawn il-kovarjanti mhux probabbli li jkollhom xi effett klinikament sinifikanti fuq l- esponiment għal trastuzumab emtansine.

the primary endpoint and other week 48 outcomes (including outcomes by key baseline covariates) for spring-2 and single are shown in table 3.
ir-riżultati f’Ġimgħa 48 (inklużi r-riżultati skont il-kovarjati prinċipali fil-linja bażi) għal spring-2 u single huma murija f’tabella 3.

the analysis explored the effects of selected covariates including body weight, age, gender, hepatic and renal function, and presence of anti-natalizumab antibodies upon pharmacokinetics.
l-analiżi esplorat l-effetti ta’ kovarjanti magħżula inkluż piż tal-ġisem, eta’, sess, funżjoni tal-fwied u tal-kliewi, u l-preżenza ta’ antikorpi għal natalizumab fuq il-farmakokinetika.

the following covariates were statistically significantly associated with a decreased risk of developing diarrhea: increasing cumulative capecitabine dose (0.1*kg) and increasing relative dose intensity in the first six weeks
il- kovarjanti li ġejjin kienu assoċjati b’ mod statistikament sinifikanti ma ’ tnaqqis fir- riskju ta ’ żvilupp ta ’ dijarea: żjieda fid- doża kumulattiva ta ’ capecitabine (0. 1 *) u żjieda fl- intensità tad- doża relattiva fl- ewwel sitt ġimgħat.